Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingo Ahrens

Showing results (31-40 of 103) with videos related to

Pageof 11
Sort By:
Thrombosis and Haemostasis|January 13, 2011
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?Ingo Ahrens, Gregory Y H Lip, Karlheinz Peter
Journal of Thrombosis and Thrombolysis|December 15, 2015
Dual pathway therapy in acute coronary syndromePeter Stachon, Ingo Ahrens, Christoph Bode, et al.
European Heart Journal|November 7, 2020
Cardiac involvement in sarcoidosis and necessary ventricular tachycardia ablationChristopher Schneeweis, Ingo Ahrens, Erol Saygili, et al.
Thrombosis and Haemostasis|June 12, 2010
New oral anticoagulant drugs in cardiovascular diseaseIngo Ahrens, Gregory Y H Lip, Karlheinz Peter
Expert Opinion on Drug Metabolism & Toxicology|August 19, 2007
Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiologyIngo Ahrens, Belinda K Smith, Christoph Bode, et al.
Discovery Medicine|June 30, 2012
Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigationIngo Ahrens, Karlheinz Peter, Gregory Y H Lip, et al.
Platelets|March 5, 2005
Distinct roles of ligand affinity and cytoskeletal anchorage in alphaIIbbeta3 (GP IIb/IIIa)-mediated cell aggregation and adhesionKarlheinz Peter, Ingo Ahrens, Meike Schwarz, et al.
Advances in Therapy|April 8, 2021
Association of Treatment Intensity and Adherence to Lipid-Lowering Therapy with Major Adverse Cardiovascular Events Among Post-MI Patients in GermanyIngo Ahrens, Artak Khachatryan, Bondo Monga, et al.
Discovery Medicine|June 30, 2012
Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugsIngo Ahrens, Karlheinz Peter, Gregory Y H Lip, et al.
Plos One|October 7, 2015
Triple Antithrombotic Therapy after Percutaneous Coronary Intervention (PCI) in Patients with Indication for Oral Anticoagulation: Data from a Single Center RegistryDawid L Staudacher, Michael Kaiser, Christoph Hehrlein, et al.
Pageof 11

Showing results (31-40 of 103) with videos related to

Sort By:
Pageof 11
Thrombosis and Haemostasis|January 13, 2011
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?Ingo Ahrens, Gregory Y H Lip, Karlheinz Peter
Journal of Thrombosis and Thrombolysis|December 15, 2015
Dual pathway therapy in acute coronary syndromePeter Stachon, Ingo Ahrens, Christoph Bode, et al.
European Heart Journal|November 7, 2020
Cardiac involvement in sarcoidosis and necessary ventricular tachycardia ablationChristopher Schneeweis, Ingo Ahrens, Erol Saygili, et al.
Thrombosis and Haemostasis|June 12, 2010
New oral anticoagulant drugs in cardiovascular diseaseIngo Ahrens, Gregory Y H Lip, Karlheinz Peter
Expert Opinion on Drug Metabolism & Toxicology|August 19, 2007
Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiologyIngo Ahrens, Belinda K Smith, Christoph Bode, et al.
Discovery Medicine|June 30, 2012
Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigationIngo Ahrens, Karlheinz Peter, Gregory Y H Lip, et al.
Platelets|March 5, 2005
Distinct roles of ligand affinity and cytoskeletal anchorage in alphaIIbbeta3 (GP IIb/IIIa)-mediated cell aggregation and adhesionKarlheinz Peter, Ingo Ahrens, Meike Schwarz, et al.
Advances in Therapy|April 8, 2021
Association of Treatment Intensity and Adherence to Lipid-Lowering Therapy with Major Adverse Cardiovascular Events Among Post-MI Patients in GermanyIngo Ahrens, Artak Khachatryan, Bondo Monga, et al.
Discovery Medicine|June 30, 2012
Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugsIngo Ahrens, Karlheinz Peter, Gregory Y H Lip, et al.
Plos One|October 7, 2015
Triple Antithrombotic Therapy after Percutaneous Coronary Intervention (PCI) in Patients with Indication for Oral Anticoagulation: Data from a Single Center RegistryDawid L Staudacher, Michael Kaiser, Christoph Hehrlein, et al.
Pageof 11